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The protective properties of antiplasmodial antibodies in malaria have been 
well established (1-3). It has also been shown that primate hosts can be protected 
against  potentially  lethal  plasmodium  infections by  vaccination  with  purified 
whole blood-stage  parasites  and adjuvants (4-8).  More recently, sera of hosts 
protected against malarial infections (9-12) and monoclonal antibodies against 
defined plasmodium antigens (13-15)  have been used to  identify plasmodium 
polypeptides that might be used for vaccination against malaria. 
Monoclonal antibodies against a Plasmodium yoelii Mr 230,000  merozoite anti- 
gen have been shown to confer passive protection when injected into BALB/c 
mice infected with P. yoelii malaria (14). A subsequent study showed that repeated 
inoculation  with  the Mr  230,000  component and  lower Mr  proteins  derived 
therefrom in  complete Freund's adjuvant  (CFA) ~ protected against  otherwise 
fatal blood-induced challenges with P. yoelii (16).  Passive protection of BALB/c 
mice by monoclonal antibodies against the P. berghei Mr 44,000 sporozoite surface 
protein (13) suggests that this antigen can confer protection against sporozoite- 
induced infections in mice. The protective nature of a P. lophurae histidine-rich 
protein (17) is under debate (18, 19). Evidence about antigens that might protect 
man against P. falcipa rum is indirect and derives from demonstration of antibody- 
mediated inhibition of parasite growth in vitro (9,  15). Two candidate antigens, 
of  approximately 82,000 and 96,000 Mr, have been identified in schizont-infected 
human  erythrocytes by  monoclonal  antibody  (20)  and  patient  sera  (9,  12), 
respectively. 
We have identified an immunogenic P.  knowlesi  glycoprotein (11,  21) that is 
expressed on the surface ofP. knowlesi-infected rhesus monkey erythrocytes (22), 
and migrates with an Mr of 74,000  in a  discontinuous electrophoresis system 
(23).  The presence of antibodies against this protein correlates positively with 
protection against P. knowlesi  malaria (11) and we have now demonstrated that 
immunization with this protein can protect rhesus monkeys against potentially 
lethal infections with P. knowlesi. 
In a limited vaccination trial of six rhesus monkeys, two animals were injected 
J  Abbreviations used in this  paper."  BSA,  bovine serum albumin; CFA, complete  Freund's adjuvant; 
DS-PAGE, dodecyl  sulfate-polyacrylamide  gel electrophoresis;  FCS, fetal calf  serum; IEF, isoelectric 
focusing; IFA, incomplete Freund's adjuvant; PMSF, phenylmethylsulfonyl  fluoride; TPCK, 
L(tosylamide-2-phenyl)-ethyl-chloromethyl-ketone. 
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with adjuvant only and four monkeys were immunized with electrophoretically 
purified Mr  74,000  P.  knowlesi  antigen  isolated  from  membranes  of schizont- 
infected erythrocytes. Upon  challenge with the W-1  variant of P.  knowlesi  the 
control monkeys developed fatal parasitemias within 7  d  (24).  The vaccinated 
monkeys, in contrast, limited the infections to peak parasitemias of between  7 
and 11%  14-16  d after challenge. Immunochemical analyses of the sera during 
vaccination  showed  that  antibodies  reacted  initially only with  the Mr  74,000 
antigen but, after the second and third booster, reacted also with related antigens 
of approximately 102,000,  140,000, and 230,000 Mr. 
Materials and Methods 
Reagents.  Reagents for dodecyl sulfate-polyacrylamide  gel electrophoresis (DS-PAGE) 
and isoelectric focusing (IEF) in polyacrylamide were as described before (11,  22-25). 
Bovine serum albumin (BSA), Triton X-100, and phenylmethylsulfonyl  fluoride (PMSF) 
were obtained from Sigma Chemical Co., St. Louis, MO. Hypaque (Na-diatrizoate) and 
chloroquine (Aralene) were purchased from Winthrop Laboratories, New York; Ficoll 
and protein A-Sepharose 4B from Pharmacia Fine Chemicals, Piscataway,  NJ. Lactoper- 
oxidase, from Boehringer Mannheim Biochemicals,  Indianapolis, IN, in 3.2 M (NH4)~SO4 
was  freed  of  ammonium  sulfate  by  dialysis  against  the  buffer  used  for  labeling. 
L(tosylamide-2-phenyl)-ethyl-chloromethyl-ketone  (TPCK)-trypsin was from Worthington 
Biochemical Corp., Freehold, NJ. RPMI 1640 with and without methionine was obtained 
from the Tufts Cancer Center, Boston, MA, and dialyzed fetal calf serum (FCS) from 
Gibco Laboratories, Grand Island, NY. [35S]methionine (>400 Ci/mmol), Nal~SI (carrier 
free in  0.1  M  NaOH,  17  Ci/mg), and  Enhance were  purchased  from  New  England 
Nuclear, Boston, MA. CFA and incomplete Freund's adjuvant (IFA) were obtained from 
Difco Laboratories, Detroit, MI. Chloramine T  and X-Omat AR X-ray film were from 
Eastman Kodak Co., Rochester, NY, and cellulose thin layer plates (Polygram Cell 300) 
were from Brinkmann Instruments, Inc., Westbury, NY. 
Monkeys and Plasmodium Strains.  Male U. S.-bred rhesus monkeys (Macaca  mulatta), 
~4 kg body weight, were obtained from Thorsen Breeding Laboratories, Enosburg Falls, 
VT. Two strains, the H strain of Malaysian origin and the W-1 variant of the W strain 
(24,  26) of P. knowlesi, were used. Both strains were passed in nonsplenectomized rhesus 
monkeys only. The H strain (maintained at the National Institutes of Health [NIH]) and 
the W-1 variant were kindly provided by Dr. J. W. Barnwell (27) and Dr. S. Cohen (24), 
respectively. The NIH isolate was used to purify the Mr 74,000 antigen and the vaccinated 
rhesus monkeys were challenged with parasites of the W-1 variant. The parasitemia was 
monitored using methanol-fixed blood smears stained with Giemsa blood stain. 
Metabolic Labeling and Solubilization of Plasmodium Antigens.  Purified schizont-infected 
erythrocytes (22,  28) were adjusted to a hematocrit of 10% using methionine-free RPMI 
1640 fortified with  10%  dialyzed, heat-inactivated FCS. The cells were incubated at a 
[35S]methionine  concentration of 0.2 mCi/ml for 3 h. The incubator was maintained at 
37°C and  equilibrated with humidified O2/C02/N2  (5.5%:5%:89.5%,  voi/vol). After 
labeling, the parasitized erythrocytes were washed three times in RPMI 1640, 0.01  M, in 
unlabeled methionine and then disrupted by nitrogen decompression (22, 28). Subcellular 
fractionation into parasites and host cell membranes was as described elsewhere (29). 
For immune precipitation the plasmodium proteins were solubilized by two sequential 
extractions in 0.01  M Hepes,  1% Triton X-100 (vol/vol), 0.002 M PMSF, pH 8.7 (21). 
The solubilization buffer for proteins to be fractionated by DS-PAGE  was 2% (wt/vol) 
0.08  M  DS,  dithiothreitol (DTT),  0.02  M  Tris-HCl,  10%  glycerol (vol/vol), pH  6.8 
("sample buffer"). 
Im munochemical Reagents and Immunoprecipitation.  Sera were drawn from the vaccinated 
rhesus monkeys before immunization, and 7 to 10 d after each of the second and third 
immunizations and after intravenous challenge with antigen. Immunoglobulin (Ig) was 
purified (30) from all sera and adjusted to 2.5 times the serum concentration. For the 148  PROTECTIVE P. KNOWLESI  Mr 74,000 ANTIGEN 
immune precipitation of the Mr 74,000 plasmodium protein, we used immune Ig from 
rhesus monkey 153 (21, 22). 
For analytical immune precipitations, 0.1 mg of [35S]methionine-labeled, Triton X- 100- 
solubilized  plasmodium  antigen  (about  106  cpm)  was  first  reacted  with  0.02  ml  of 
nonimmune Ig and 0.08 ml of 50% (vol/vol) hydrated protein A-Sepharose 4B for 60 
min. The preabsorbed antigen was then equilibrated with 0.02 ml of immune Ig for 90 
min, at 4°C and 37 °C, followed by an incubation with 0.08 ml of protein A-Sepharose at 
4°C for 60 min. Proteins bound nonspecifically were eluted from the protein A-Sepharose 
by three washes  in 0.13 M NaCl, 0.02 M Tris-HCI, 1% Triton X-100 (vol/vol); 0.01  M 
methionine, 0.02% BSA (wt/vol), pH 8.0 ("washing buffer"), one wash in washing buffer 
containing LiCI (0.5 M), and one in washing buffer without BSA. In control experiments 
the antigen was incubated with preimmune Ig for both reactions. 
For the large scale immune precipitation, five 10-mg aliquots of Triton X- 100-extracted 
membrane antigens (90% unlabeled and 10% [~SS]methionine-labeled  protein; see below) 
were preadsorbed as described above and then reacted with 2 ml of immune Ig for 90 
min at 37 and 4°C. The antigen-antibody complexes were deposited using 5 ml of a 50% 
(vol/vol) protein A-Sepharose. The protein A-Sepharose beads were washed extensively 
as  described above.  Specifically bound  antigens  were  eluted  with  sample  buffer and 
fractionated on analytical or preparative scale DS-polyacrylamide slab  gels  (23).  After 
electrophoresis the gels  were dried without fixation and the  protein  was  localized by 
autoradiography. 
Isolation of the Mr 74,000 P. knowlesi Component.  The Mr 74,000 protein was isolated 
from  purified  membranes  of P.  knowlesi-infected  rhesus  erythrocytes (containing  4-6 
nuclei schizonts). Of the 4 ×  10 H cells used for subcellular fractionation (28, 29, 31), 4 × 
10 l° were labeled metabolically with [35S]methionine as described above. One half of the 
host cell membrane proteins were solubilized by two sequential extractions in Triton X- 
100 and immune precipitated with rhesus immune Ig (monkey 153) (11); the other half 
was equilibrated in sample buffer. The proteins of both samples were fractionated on 
multiple slab gels by DS-PAGE (23).  ssS autoradiograms of the dried, unfixed gels were 
used  to  identify the Mr  74,000  plasmodium  protein that was  isolated in  two separate 
batches;  one from gels  in  which  the  DS-solubilized host cell membrane proteins were 
fractionated, the other from gels  containing the immune-precipitated parasite protein. 
The gel strips containing the protein were recovered, rehydrated in siliconized glass tubes 
using Na-phosphate (0.005 M), pH 8.0. The extraction was terminated when 70-80% of 
the  protein  was  extracted by three  sequential  equilibrations of the  gel  pieces  in  Na- 
phosphate/DS (0.005 M:0.1%,wt/vol), pH 8.0. The protein was quantitated fluorometr- 
ically (32). 
The purity of the Mr 74,000 component was assessed by reelectrophoresis and IEF (25, 
35  125  30) of the [  S]methionine-labeled protein or by the chloramine T  technique after  I 
labeling. The latter procedure was chosen as a most sensitive tool to search for possible 
protein  contaminants  that  were  derived from  the  host  cell  membrane and  were  not 
metabolically labeled with [35S]methionine. 
Vaccination of Rhesus Monkeys.  Six male rhesus monkeys (Nos. 163-166, 170, and 171) 
previously unexposed to malaria were selected for the vaccination trial with the Mr 74,000 
protein. The extracted proteins, electrophoretically purified protein (0.6  mg) and im- 
mune-precipitated sample (0.5 mg), were each split into eight aliquots for immunization 
of rhesus monkeys Nos.  165 and  166, and  Nos.  170 and  171,  respectively. For each 
immunization, 0.1 ml of antigen (0.07 mg) was mixed with 0.15 ml CFA and injected half 
intramuscularly and half subcutaneously at multiple sites.  The injections were repeated 
with IFA for the first and second booster immunization given at 3-wk intervals. The third 
booster immunization  was  given  intravenously without  IFA  3  wk  later,  10  d  before 
challenge of the  monkeys with  104  freshly drawn  schizont-infected erythrocytes (W-1 
variant of P. knowlesi). Rhesus monkeys 163 and 164 were injected according to the same 
schedule with CFA and IFA only and challenged with the same number of viable parasites. 
x2"~I-labeting of Plasmodium  Proteins.  After  DS-PAGE the  proteins were  localized by 
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subjected to formic acid oxidation before they were iodinated and digested by TPCK- 
trypsin. Performic acid was produced by co-incubation of formic acid and 30%  H20~ 
(19:1, vol/vol) for 150 min at 0 °  C. The protein-containing gel pieces were then incubated 
in performic acid/methanol (8:2, vol/vol) for 30 min at 4°C. The chloramine T technique 
(33) was used to achieve high specific activity ~5I labeling of cross-reacting plasmodium 
components with Mr of approximately 74,000,  102,000,  140,000,  and  230,000.  The 
iodination was performed in polyacrylamide (34) with modifications as described (25). 
Triton X-100-solubilized proteins from membranes of schizont-infected erythrocytes were 
labeled with ~25I using lactoperoxidase and H202 (22) and used for immune precipitation 
with vaccination sera. 
Trypsin Digestion of Plasmodium Antigens.  For cleavage with TPCK-trypsin, dried gel 
pieces containing ~2~I-labeled plasmodium Mr  74,000,  102,000,  140,000,  and 230,000 
proteins were hydrated with 0.05 mi of NH4HCO3 (0.05 M), pH 7.8. TPCK-trypsin (0.5 
mg/ml) in  0.05  M  NH4HCOs  was added in  the same volume that was  required  for 
complete hydration of gel pieces.  Trypsinization was for 40 h  at 37°C with a  second 
addition of 0.05 mg TPCK-trypsin after 16 h. Controls were run as described (25). 
Peptide Mapping.  Two-dimensional thin layer peptide mapping was used to define the 
positions of peptides in a two-dimensional grid. About 5 ×  l0 B  cpm ~25I-labeled peptides 
were applied to a  10 x  10-cm thin layer chromatography plate near the cathode. The 
plate was then moistened with acetic acid/formic acid/H20 (I 5%:5%:80%, vol/vol) and 
a  dye  mixture  of orange  G/acid  fuchsin (2%:1%,  wt/vol)  spotted  near  the  anode. 
Electrophoresis in the first dimension, at 400 V, was terminated when the dye reached 
the sample spot.  The plates were dried  under cold air.  Chromatography in butanol/ 
pyridine/acetic acid/H20 (32.5:25:5:20, vol/vol) was at right angles to the first dimen- 
sion. After drying, the peptide maps were developed by ~5I autoradiography. 
To prove the identity of peptides derived from the immune-precipitated plasmodium 
components  with Mr  of approximately  74,000,  102,000,  140,000,  and  230,000,  we 
localized individual peptides by ~I autoradiography. The peptides were scraped off the 
cellulose thin layer plates and eluted from the cellulose with acetic acid/formic acid/ 
water (15%:5%:80%,  vol/vol). In all reelectrophoresis-rechromatography experiments, 
identical amounts of peptides, as determined by • 25I radioactivity were rerun on thin layer 
plates. 
Results 
Isolation and Purity of the Mr 74,000 P. knowlesi Antigen.  Electrophoretic isola- 
tion of the Mr 74,000 protein from membranes of schizont-infected erythrocytes 
and purification by immune precipitation  followed by DS-PAGE both  yielded 
,~0.5  mg from  50  mg of membrane  protein.  This  indicates  that  the  protein 
represents  ~  1%  of the  total  membrane  protein.  The  Mr  74,000  component 
could  be  purified  electrophoretically (with  or  without  immune  precipitation) 
from  most  gels  as  a  homogeneous  component  yielding  a  single  band  upon 
reelectrophoresis. This was true whether the protein was monitored by metabol- 
ically incorporated [~S]methionine or by extrinsic ~25I labeling (Fig.  1, lanes 2, 
5, and 6). 
As is shown in Fig. 2, the ~25I-labeled, purified Mr 74,000  protein focused in 
polyacrylamide  near  an  isoelectric  point  (pI)  of  5.2.  Identical  results  were 
obtained  whether  the  protein  was  isolated  by  DS-PAGE  only or  by  immune 
precipitation  and  DS-PAGE.  Neither  DS-PAGE  nor  IEF  of the  metabolically 
labeled and extrinsically iodinated Mr 74,000 protein showed detectable contam- 
ination by other plasmodium and/or host cell polypeptides. 
Vaccination.  The  intravenous  inoculation  of  104  freshly  drawn  P.  knowlesi 
schizont-infected rhesus erythrocytes produced potentially fatal parasitemias in 150  PROTECTIVE P. KNOWLESI M~ 74,000 ANTIGEN 
FIGURE  1.  DS-PAGE  of  the  purified  P.  knowlesi Mr  74,000  and  230,000  proteins  from 
membranes of schizont-infected rhesus erythrocytes. Mr, x  10 -3. Lane l: Mr 230,000 protein, 
[~SS]methionine autoradiogram; lane 2: Mr 74,000 protein, formic acid oxidation, Coomassie 
blue staining; lane 3: Mr 230,000 protein, formic acid oxidation, Coomassie blue staining; lane 
4: Mr  230,000  protein,  formic  acid  oxidation,  [35S]methionine  autoradiogram;  lane  5:  Mr 
74,000  protein  (105  cpm),  formic acid oxidation and  ~SI-labeling with  chloramine  T,  ~251 
autoradiogram;  lane  6: M,  74,000  protein  (5  ×  106  cpm),  formic acid oxidation and  ~25I- 
labeling with  chloramine  T,  ~5I  autoradiogram;  lane  7:  Mr  230,000  protein,  formic  acid 
oxidation and l~51-1abeling with chloramine T, l~sI autoradiogram. 
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FIGURE  2.  IEF of P. knowlesi proteins from membranes of scbizont-infected rhesus erythro- 
cytes. The membrane proteins and the purified Mr 74,000 component were labeled with l~SI 
using the chloramine T  technique.  Abscissas give the pH gradient and the gel fractions, the 
ordinate the 125I radioactivity (cpm). (--) membranes of infected erythrocytes; (- -  -) purified 
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FIGURE 3.  P.  knowlesi  (W-l-variant)  infections  in  rhesus monkeys vaccinated  with  the P. 
knowlesi Mr 74,000 protein (see text for details). Abscissa gives the days after challenge of the 
monkeys with 104 viable P. knowlesi schizonts. Ordinate indicates the percent parasitemias. (O), 
(O) rhesus monkeys 163 and 164 injected with complete adjuvant only; (A), (&) rhesus monkeys 
165 and 166 vaccinated  with electrophoretically  purified P. knowlesi Mr 74,000 protein; (F-l), 
(11) rhesus  monkeys 170 and  171  vaccinated  with  immunoprecipitated, electrophoretically 
purified P. knowlesi M, 74,000 protein. 
rhesus monkeys 163 and 164, injected with adjuvants only. In these two monkeys 
a patent parasitemia of ~0.1% was first detected on days 4 or 5 (Fig. 3). Within 
7 d, the parasitemia rose to lethal levels of 25 and 39% for rhesus monkeys 163 
and  164,  respectively. At this  time, the animals were rescued by chloroquine 
injections and transfusion of "~40 ml of packed, washed rhesus erythrocytes. 
After  inoculation  with  104  viable  schizont-infected erythrocytes, the  four 
rhesus monkeys (Nos.  165,  166,  170, and 171) that were immunized with the P. 
k~zowlesi Mr  74,000  protein  exhibited  a  delayed onset  of patent  parasitemia 
(~0.1%) on days 8 or 9 postinoculation. After an additional 6-7  d, the para- 
sitemias  peaked  between  7  and  11%  (Fig.  3).  Thereafter, all  four  monkeys 
cleared the parasites spontaneously and recovered without drug treatment. Only 
monkey  166  developed an  anemia on  day  16  postinoculation (hematocrit of 
22%), at a time of decreasing parasitemia. On day 17, he required a transfusion 
of 20 ml washed, packed erythrocytes, but no chloroquine treatment. Monkeys 
165,  170, and 171  underwent self-cure with anemias at expected levels. Weekly 
monitoring of all  monkeys for four more months did not reveal recrudescent 
plasmodium infections. 
With the initiation of self-cure of monkeys 165, 166, 170, and 171, no schizonts 
were seen  in  the  peripheral  blood.  However, a  low  level  of reinfection was 
suggested by the persistence of (decreasing) concentrations of predominantly 
normal ring and trophozoite stages.  The more mature trophozoites appeared 
pycnotic. 
Antigen  Reactivity of the Vaccination Sera.  No appreciable differences in quali- 
tative antibody responses to the Mr 74,000 antigen could be observed in the four 
vaccinated rhesus monkeys, 165,  166,  170,  and  171.  The results shown were 152  PROTECTIVE P. KNOWLESIMr 74,000 ANTIGEN 
obtained  with  pooled  sera.  None  of the  preimmune Ig  nor  Ig  from  rhesus 
monkeys 163 and  164 specifically deposited any P. knowlesi component (Fig. 4, 
lane 4).  After the first booster immunization, only the Mr 74,000 protein was 
precipitated from membranes of P. knowlesi-infected  rhesus erythrocytes (Fig.  4, 
lanes  1  and  7).  However,  Ig  obtained  after  the  second  and  third  booster 
immunization deposited P. knowlesi components with Mr near 230,000, 140,000, 
and  102,000,  in addition to the Mr 74,000 protein (Fig.  4,  lanes 2,  3,  and 8). 
The apparent antigenic relatedness of these proteins was further examined by 
tryptic peptide mapping. 
Peptide Homology Between the Mr 74,000 Proteins and Immune Precipitated Higher 
Mr Components.  Performic acid oxidation before extrinsic iodination and tryptic 
peptide  mapping resulted  in  a  reproducible degradation  of the Mr  230,000 
protein into a  Mr  74,000  and  into components with Mr  between  70,000  and 
65,000 (Fig.  1, lanes 1, 3, 4, and 7). 
Oxidation and chloramine T  radioiodination degraded the M~ 230,000 com- 
ponent into a Mr 74,000 protein and components of smaller Mr. In contrast, the 
Mr 74,000,  102,000, and 140,000 components were not degraded by oxidative 
denaturation. 
The structural relatedness between the Mr 230,000,  140,000,  102,000, and 
74,000 components was demonstrated by the high degree of homology in their 
FIGURE 4.  DS-PAGE ofP. knowlesi protein specifically  precipitated by immune Ig from sera 
of vaccinated rhesus monkeys. Constant amounts of membrane protein (0.1  mg) from [35S]- 
methionine-labeled P.  knowlesi-infected rhesus erythrocytes were preincubated with Ig from 
preimmune serum and protein A-Sepharose followed by specific deposition of the antigen by 
immune Ig and protein A-Sepharose. Lanes I-6: [35S]methionine autoradiograms; lanes 7 and 
8: ~I autoradiograms. Lane 1: P. knowlesi proteins deposited by Ig after the 2nd vaccination; 
lane 2: P. knowlesi proteins deposited by Ig after the 3rd vaccination; lane 3: P. knowlesi proteins 
deposited by  Ig after  four  injections of the Mr  74,000  protein;  lane  4:  double  immune 
precipitaton of P.  knowlesi  proteins as  in  I-3,  but  using  Ig from  preimmune  serum  only 
(control); lane 5:  purified Mr 74,000  protein used for vaccination; lane 6:  [35S]methionine 
labeled proteins from membranes of schizont-infected rhesus erythrocytes; lane 7: P.  knowlesi 
proteins, extrinsically labeled with  1251 and  chloramine T,  deposited by  Ig after  the  2nd 
injection of the Mr 74,000 protein; lane 8: P.  knowlesi proteins, extrinsically labeled with ~25I 
and chloramine T, deposited by lg after the 4th injection of the Mr 74,000 protein. SCHMIDT-ULLRICH, LIGHTHOLDER,  AND  MONROE  153 
FIGURE  5.  Two-dimensional  thin layer peptide maps ofP. knowlesi  Mr 74,000 and 230,000 
proteins from membranes of schizont-infected  rhesus erythrocytes. The proteins were dena- 
tured  by formic acid oxidation, labeled with ~25I using the chloramine T  technique, and 
digested with TPCK-trypsin. z~sI autoradiograms of (A) tryptic peptides of the MT 74,000 
protein, (B) tryptic peptides of the M, 230,000 protein, (C-F) reelectrophoresis/rechromatog- 
raphy of peptides 1,3, 6, and 9 isolated and combined from maps of both the Mr 74,000 and 
230,000 proteins. The peptides of the Mr 230,000 protein that yields the largest number of 
peptides are labeled 1 through 16. The peptides numbered in the Mr 74,000 protein map are 
identical to those of the 230,000 protein, as exemplified  for peptides 1, 3, 6, and 9. 
~25I-tryptic peptide maps (Figs. 5  and 6).  As the Mr 230,000  yielded the largest 
number of peptides, the map of this protein was used to assign a number to each 
peptide.  Identical  numbers  in  maps  of  components  with  Mr  near  140,000, 
102,000, and 74,000 indicate that these peptides are identical to those of the Mr 
230,000 protein as proven by co-migration of the isolated peptides upon reelec- 
trophoresis-rechromatography. These results are illustrated for the Mr 230,000 
and 74,000  antigens in Fig. 5, C-F on peptides  1,  3, 6, and 9, and on the same 
peptides for all four antigens in Fig. 6, C-F. 
Discussion 
Immunization of four rhesus  monkeys with a  Mr  74,000  P.  knowlesi  protein 
purified  from  membranes  of schizont-infected  rhesus  erythrocytes conferred 
protection against otherwise fatal blood-induced infections with the W-1 variant 
of P.  knowlesi  (24).  While  104  viable  W-1  schizonts  produced  fatal  infections 
within  7-8  d  in  two  rhesus  monkeys that  were  injected  with  adjuvant alone, 154  PROTECTIVE P. KNOWLESI Mr 74,000 ANTIGEN 
FIGURE 6.  Two-dimensional  thin layer peptide maps of  P. knowlesi  M, 102,000 and 140,000 
proteins from membranes of schizont-infected  rhesus erythrocytes. The proteins were dena- 
tured  by formic acid oxidation, labeled with ~5I  using the chloramine T  technique, and 
digested with TPCK-trypsin. ~25I autoradiograms of (A) tryptic peptides of the Mr 102,000 
protein, (B) tryptic peptides of the Mr 140,000 protein, (C-F) reelectrophoresis/rechromatog- 
raphy of peptides 1, 3, 6, and 9 isolated and combined from maps of the components with Mr 
near 74,000,  102,000, 140,000, and 230,000. The peptides numbered in the maps of Mr 
102,000 and  140,000 proteins are identical to those of the 230,000 protein (see Fig. 5) as 
exemplified  for peptides 1, 3, 6, and 9. 
protection of the vaccinated monkeys was indicated by delayed onset of patent 
parasitemia and maximum parasitemias between only 7 and 11% on days 14 and 
15  post-challenge.  During the period of self-cure, limited reinfection was indi- 
cated by the presence  of normal  ring and trophozoite stages, but no schizont- 
infected erythrocytes were seen in the peripheral blood. Immunochemical eval- 
uation of the vaccination sera revealed that during the first two immunizations 
antibody production was confined to the Mr 74,000 component. Further immu- 
nizations, irrespective of the antigen purification technique, induced antibodies 
that reacted not only with the Mr 74,000  protein  but also with components of 
Mr  near  102,000,  140,000,  and  230,000.  Tryptic peptide  homology between 
these proteins is compatible with the immunological cross-reactivity. 
Vaccination of rhesus monkeys with the M~ 74,000 P. knowlesi schizont antigen 
conferred protection against P.  knowlesi similar to that described for a P. yoelii Mr 
230,000  merozoite  antigen  in  this  murine  malaria  (16).  Immunizations  with 
purified antigens (15) and with various preparations of whole-blood-stage para- 
sites  (4-8)  required  transient  parasitemias  of a  maximum  of  15%  before  the SCHMIDT-ULLR1CH,  LIGHTHOLDER,  AND  MONROE  155 
previously induced immunity led to self-control of the infections. The mechanism 
of protection contrasted to immunity with very low transient parasitemia that 
has been observed in some rhesus monkeys after vaccination with P.  hnowlesi 
merozoites (24, 35) and has led to the proposal that the complete interruption 
of plasmodium infections occurred at the merozoite stage (35).  However, per- 
sistent low level parasitemias in our vaccinated rhesus monkeys during the period 
of self-cure indicated that the parasites were affected not only during merozoite 
release or reinvasion but also during schizont maturation. The specific action of 
anti-Mr 74,000 antibodies on P. knowlesi schizonts has been confirmed in in vitro 
experiments in which these antibodies significantly inhibited the maturation and 
biosynthetic activity of parasites (R. Schmidt-Ullrich, unpublished results). These 
data fit observations showing growth retardation of P. falciparum schizonts and 
inhibition of merozoite release when grown in vitro in the presence of sera from 
immune Aotus monkeys (36).  Our own and  others'  results  (36)  suggest that 
antibodies against plasmodium antigens of schizont-infected erythrocytes could 
interrupt the erythrocyte schizogony at that stage. 
In the absence of detectable contamination by other proteins, the most likely 
reason for immunochemicai cross-reactivity between the Mr 74,000 component 
and  the  Mr  102,000,  140,000,  and  230,000  proteins  represented  antigenic 
homology. Tryptic peptide analyses of these proteins indicated that a significant 
portion of the Mr 74,000 protein appeared to be contained in the Mr 230,000 
component. In addition,  this  protein could, upon oxidative denaturation, be 
disintegrated into polypeptides with Mr near and below 74,000. Considering the 
peptide homology between  the Mr  74,000  protein  and  the MT  102,000  and 
140,000 components, we have to conclude that the Mr 230,000 protein repre- 
sents  a  precursor  that  is  processed  by  controlled  proteolysis  to  smaller Mr 
components as has been documented for one other plasmodium species (16). 
The immune reactivity of the Mr  102,000,  140,000, and 230,000 components 
after  more  than  two  immunizations of rhesus  monkeys with  the Mr  74,000 
protein is most likely due to an increased avidity and/or a broader specificity of 
the antibodies and to some structural heterogeneity of the reacting proteins. 
We have demonstrated that the Mr 74,000 P. knowlesi protein in membranes 
of schizont-infected rhesus  erythrocytes represents  a  protective antigen  that 
induces antibodies active against the schizont-stage. We have also shown that the 
Mr 74,000 antigen is common to at least two different P.  knowlesi strains (22), 
because the antigen  for  immunization was  isolated from rhesus erythrocytes 
infected with the H  strain while the animals were challanged with the heterolo- 
gous W strain (24). These results confirm our previous immunochemical  analyses 
showing that there are cross-reacting Mr 74,000 antigens in membranes of rhesus 
and  human erythrocytes infected with different strains  of P.  knowlesi and P. 
falciparum,  respectively (21,  22,  37).  The  homology between  the Mr  74,000 
proteins of P. knowlesi and P. falciparum is currently being investigated in more 
detail. 
Summary 
The immunogenic Plasmodium  knowlesi (H strain) Mr 74,000 protein in mem- 
branes of schizont-infected rhesus erythrocytes was purified on a large scale, free 156  PROTECTIVE P. KNOWLESI  Mr 74,000 ANTIGEN 
of other polypeptides as monitored  by dodecyl sulfate polyacrylamide gel elec- 
trophoresis  and  isoelectric focusing.  In  a  limited  vaccination  trial,  four rhesus 
monkeys were immunized  four consecutive times  with  the Mr  74,000  protein 
and  Freund's complete and incomplete adjuvants.  Two monkeys were injected 
with adjuvant only.  Upon challenge  with  104 viable P.  knowlesi schizonts of the 
heterologous W strain,  the control monkeys developed fatal parasitemias after 7 
d.  In  contrast,  the  vaccinated  monkeys  exhibited  a  delayed  onset  of patent 
parasitemias and  underwent self-cure on days  ! 4 to  16 after peak parasitemias 
of between  7  and  11%.  The  protective  immunity  that  was  induced  crossed 
different strains  of P.  knowlesi.  Blood smears at the time of cure demonstrated 
limited reinfection, as indicated by the presence of normally appearing ring and 
trophozoite  stages.  The  absence  of schizont  stages  in  the  peripheral  blood 
suggested a  specific interruption  of the  erythrocytic schizogony at  that  stage. 
Immunochemical analyses of the rhesus sera revealed antibody only against the 
Mr  74,000  protein  after  the  first  two immunizations.  Upon  repeated  antigen 
injection, antibodies reacted with components of Mr of approximately  102,000, 
140,000, and 230,000 in addition to the Mr 74,000 protein. Besides immunolog- 
ical cross-reactivity, relatedness  between all  four immune-precipitated  proteins 
was  indicated  by a  >50%  tryptic  peptide  homology,  suggesting  that  the  Mr 
230,000  component  represents  a  precursor  protein  that  is cleaved within  the 
infected erythrocyte into proteins with Mr of approximately  140,000,  102,000, 
and 74,000. 
We thank  Dr.  D. F. H. Wallach for continuous interest in the progress of this work and 
for critical review of the manuscript. 
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